Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million

Full Year Revenue of Approximately $62.3 MillionCompany Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational SynergiesFARMINGDALE, N.Y., July 10, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (a??Misonix,a?? the a??Company,a?? a??we,a?? a??usa?? or a??oura??), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced preliminary unaudited fiscal 2020 fourth quarter revenue for the three months ended June 30, 2020.Fiscal Fourth Quarter Revenue
Misonixa??s revenue for the three months ended June 30, 2020 was approximately $13.5 million, compared to $9.8 million in the prior year period. Due to Misonixa??s acquisition of Solsys Medical, which was completed in the first fiscal quarter of 2020, the prior year period revenue excludes TheraSkin revenue of $7.8 million. On a pro-forma basis, including the TheraSkin revenue from the three-month period ended June 30, 2019, revenue declined approximately 23% for the fourth quarter and increased approximately 8% for the full fiscal year ended June 30, 2020. For the fourth quarter of fiscal 2020, surgical revenue declined approximately 36% and wound revenue declined approximately 11%, compared with the fourth quarter of fiscal 2019 and including TheraSkin revenue in the fourth quarter of fiscal 2019 on a pro forma basis. At June 30, 2020, the Company had approximately $38 million in cash.Misonix President and Chief Executive Officer, Stavros Vizirgianakis, said, a??I am extremely proud of the entire Misonix team for their unwavering commitment and success in navigating during this global pandemic. While we have experienced a significant slowdown in elective procedures brought on by the onset of COVID-19 in recent months, procedure volumes in the domestic market showed improvement during May and June. Although it is difficult to predict what the impact of COVID-19 will be in the coming months in both the domestic and international markets, we remain prepared to adjust our business accordingly.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2021    »